Organization · Other
Commodore Capital LP
Commodore Capital LP is a healthcare crossover hedge fund based in New York, specializing in biopharmaceutical investments. The firm focuses on long-term minority investments in small-cap public and late-stage private companies developing innovative medical products.
Overview
What Commodore Capital LP does
What Commodore Capital LP is
Commodore Capital LP is a healthcare crossover hedge fund based in New York, specializing in biopharmaceutical investments. The firm focuses on long-term minority investments in small-cap public and late-stage private companies developing innovative medical products.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Other
- Founded
- Founded in 2019
- Approximate age
- About 7 years
- Structured capabilities
- Funder
- Last reviewed
- April 22, 2026
Official channels
Find Commodore Capital LP elsewhere
Open the official website or a supported primary organization account.
Capability profile
Commodore Capital LP as a funder
Investment thesis
Commodore Capital LP focuses on science-driven, long-term minority investments in innovative biopharmaceutical and medical products companies, particularly those developing treatments that significantly improve patients' lives through scientific breakthroughs, genetic medicines, and cellular therapies.
Focus narrative
Commodore Capital specializes in healthcare investments, particularly in biopharmaceuticals. The firm targets small-cap public and late-stage private companies that are developing groundbreaking treatments. Their investment strategy emphasizes long-term partnerships with companies that are committed to scientific innovation and improving patient outcomes.
Value beyond capital
Commodore Capital adds value to its portfolio companies through strategic guidance, leveraging its deep industry expertise and network in the biopharmaceutical sector. The firm focuses on fostering innovation and supporting the development of transformative therapies that can significantly impact patient care.
Terms and economics
- Typical check
- $1,000,000–$15,000,000
- Sweet spot
- $5,000,000
Focus and fit
- Stages
- Series A · Series B · Growth Equity
- Regions
- North America
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 34
Portfolio context
Commodore Capital has backed over 34 companies across public and private markets, including notable public holdings such as Relay Therapeutics, Alkermes, Tyra Biosciences, Xenon Pharmaceuticals, and Spyre Therapeutics.
Common questions
What to know about Commodore Capital LP
Upseed classifies Commodore Capital LP under the Other organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 22, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.